From the Journals

Dieting and Gout: Intensive Weight Loss Not Especially Helpful for Symptoms


 

TOPLINE:

An intensive weight loss program is safe for individuals with gout and obesity but does not ease gout symptoms compared with a “control diet” with basic nutritional counseling.

METHODOLOGY:

  • Weight loss is recommended as a gout management strategy, despite little clinical evidence.
  • Researchers recruited 61 patients with gout and obesity to participate in a 16-week, randomized, nonblinded, parallel-group trial in Denmark.
  • A total of 29 participants were assigned to an intensive, low-calorie diet with provided meal replacements.
  • Another 32 participants were assigned to the “control diet” with basic nutritional counseling.

TAKEAWAY:

  • Patients in the intensive group lost more weight (−15.4 kg/34 lbs) than those the control group (−7.7 kg/17 lbs).
  • There were no differences in pain, fatigue, or gout flares between the two groups.
  • Weight loss was associated with reduction in serum urate (SU).
  • Patients in the intervention group had a numerically larger mean SU change (−0.6 mg/dL) than the control group (−0.3 mg/dL), but this difference was not statistically significant.

IN PRACTICE:

Weight loss can lower SU levels, but this did not translate to improved gout symptoms.

SOURCE:

Robin Christensen, PhD, and Kristian Zobbe, MD, PhD, of the Parker Institute at Bispebjerg and Frederiksberg Hospital in Copenhagen, Denmark, were co-first authors of the study, published on January 2, 2024, in Arthritis & Rheumatology.

LIMITATIONS:

The study had a relatively small sample size and short-term intervention period, which may have made it difficult to detect differences between the intervention and control groups. Patients in the control group lost a significant amount of weight, which also affected comparisons between the two groups.

DISCLOSURES:

Several of the authors disclosed financial relationships with pharmaceutical companies. The Parker Institute, which funded the study, is supported by grants from the Oak Foundation and the Danish Rheumatism Association.

A version of this article appeared on Medscape.com.

Recommended Reading

Colchicine’s 2010 price spike had major impact on gout care
Federal Practitioner
URAT1 inhibitor shows ‘substantial’ uric acid reduction in phase 2 gout trial
Federal Practitioner
Investigational uricase-based gout drug meets primary endpoints in phase 3 trials
Federal Practitioner
Gout linked to smaller brain volume, higher likelihood of neurodegenerative diseases
Federal Practitioner
FDA OKs low-dose colchicine for broad CV indication
Federal Practitioner
EULAR issues imaging recommendations for crystal-induced arthropathies
Federal Practitioner
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
Federal Practitioner
FDA approves canakinumab for gout flares
Federal Practitioner
Diabetes drug class appears to reduce recurrent gout flares
Federal Practitioner
Approximately 20% of U.S. adults are diagnosed with arthritis
Federal Practitioner